EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alnylam Pharmaceuticals's Enterprise Value is €36,179 Mil.
Alnylam Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €551 Mil. Therefore, Alnylam Pharmaceuticals's EV-to-FCF for today is 65.64.
The historical rank and industry rank for Alnylam Pharmaceuticals's EV-to-FCF or its related term are showing as below:
HAM:DUL'
s EV-to-FCF Range Over the Past 10 Years
Min: -1138.41 Med: -20.43 Max: 2276.99
Current: 62.27
During the past 13 years, the highest EV-to-FCF of Alnylam Pharmaceuticals was 2276.99. The lowest was -1138.41. And the median was -20.43.
HAM:DUL's EV-to-FCF is ranked worse than 82.37% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs HAM:DUL: 62.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alnylam Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Alnylam Pharmaceuticals's share price for today is €279.10.
Alnylam Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.132.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alnylam Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's EV-to-FCF falls into.
Alnylam Pharmaceuticals's current Enterprise Value is €36,179 Mil.
Alnylam Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €551 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (HAM:DUL) has a EV-to-FCF of 65.64 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alnylam Pharmaceuticals and its competitors. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #271 out of 329 companies in the Biotechnology industry, placing it in the top 82.4%.
Is Alnylam Pharmaceuticals' EV-to-FCF too high?
Alnylam Pharmaceuticals' current EV-to-FCF is 65.64. The Biotechnology industry median EV-to-FCF is 16.38. Alnylam Pharmaceuticals' value of 65.64 is 300.7% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #271 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' EV-to-FCF compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #271 out of 329 companies for EV-to-FCF. This places Alnylam Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 16.38. Alnylam Pharmaceuticals' value of 65.64 is 300.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current EV-to-FCF of 65.64 is 300.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current EV-to-FCF is 65.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (HAM:DUL) is currently considered Significantly Undervalued. The stock's GF Value™ is €452.87, compared to a current price of €279.10 — trading 38.4% below its estimated fair value. The current EV-to-FCF is 65.64 and 300.7% above the Biotechnology industry median of 16.38. Alnylam Pharmaceuticals' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Alnylam Pharmaceuticals (HAM:DUL), the current EV-to-FCF is 65.64 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (HAM:DUL) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of €279.10 is trading 38.4% below its estimated GF Value™ of €452.87.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for HAM:DUL:
EV-to-FCF: 65.64
GF Value™: €452.87 vs. price of €279.10 (38.4% below fair value)
Industry Position: 300.7% above the Biotechnology median (#271 of 329)
No single metric tells the full story. See the HAM:DUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
74GF Score
Get the complete analysis for HAM:DUL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:DUL has been successfully added to your 
